204 related articles for article (PubMed ID: 11831646)
1. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.
Hazlehurst LA; Dalton WS
Cancer Metastasis Rev; 2001; 20(1-2):43-50. PubMed ID: 11831646
[TBL] [Abstract][Full Text] [Related]
2. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
Hazlehurst LA; Damiano JS; Buyuksal I; Pledger WJ; Dalton WS
Oncogene; 2000 Sep; 19(38):4319-27. PubMed ID: 10980607
[TBL] [Abstract][Full Text] [Related]
3. Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.
Fei M; Hang Q; Hou S; Ruan C
Int J Hematol; 2013 Oct; 98(4):446-55. PubMed ID: 24037419
[TBL] [Abstract][Full Text] [Related]
4. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
6. Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.
Fei M; Hang Q; Hou S; He S; Ruan C
Mol Cell Biochem; 2014 Jan; 386(1-2):177-87. PubMed ID: 24170542
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
8. Integrin-mediated drug resistance in multiple myeloma.
Damiano JS; Dalton WS
Leuk Lymphoma; 2000 Jun; 38(1-2):71-81. PubMed ID: 10811449
[TBL] [Abstract][Full Text] [Related]
9. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
10. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
11. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin.
Kim HP; Kim TY; Lee MS; Jong HS; Kim TY; Lee JW; Bang YJ
Biochim Biophys Acta; 2005 Mar; 1743(1-2):151-61. PubMed ID: 15777850
[TBL] [Abstract][Full Text] [Related]
13. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.
Liu H; Guo D; Sha Y; Zhang C; Jiang Y; Hong L; Zhang J; Jiang Y; Lu L; Huang H
Aging (Albany NY); 2020 Jun; 12(11):11100-11115. PubMed ID: 32526706
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
16. Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.
Liu J; Wang Y; He S; Xu X; Huang Y; Tang J; Wu Y; Miao X; He Y; Wang Q; Liang L; Cheng C
Hematology; 2016 Dec; 21(10):603-612. PubMed ID: 27319807
[TBL] [Abstract][Full Text] [Related]
17. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix in bone marrow can mediate drug resistance in myeloma.
Vincent T; Mechti N
Leuk Lymphoma; 2005 Jun; 46(6):803-11. PubMed ID: 16019524
[TBL] [Abstract][Full Text] [Related]
19. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Hazlehurst LA; Argilagos RF; Emmons M; Boulware D; Beam CA; Sullivan DM; Dalton WS
Cancer Res; 2006 Feb; 66(4):2338-45. PubMed ID: 16489039
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]